July 21st 2025
Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.
Women Who Receive Organ-Sparing Robotic Cystectomy Experience Preserved Sexual, Urinary Function
December 7th 2021A retrospective study presented at the 22nd SUO Annual Meeting revealed that pelvic organ–preserving robot-assisted radical cystectomy allowed women to return to sexual activity post-surgery.
18F-fluciclovine PET/CT Significantly Influences ADT Plans for Patients with Prostate Cancer
December 6th 2021A secondary analysis of 2 treatment alterations studies demonstrated that 18F-fluciclovine PET/CT scans play a pivotal role in determining if androgen deprivation therapy is appropriate for patients with prostate cancer.
UGN-102 Induces Durable Responses in Patients with Low-Grade Intermediate-Risk NMIBC
October 24th 2021Approximately 73% of patients with NMIBC who experienced a complete response after non-surgical primary chemoablation using mitomycin-containing reverse thermal gel UGN-102 remained disease free at 9 months.
Axitinib/Pembrolizumab Combination Improves Survival in Metastatic RCC, But Only Marginally
October 17th 2021A real-world survival analysis showed that patients with metastatic RCC treated with axitinib plus pembrolizumab did not experience significantly improved survival outcomes compared with patients treated with ipilimumab plus nivolumab.
Apalutamide Induces Impressive PSA Response and Solid Adherence Rates in Men with nmCRPC
September 23rd 2021Real-world evidence recently presented at the 2021 AUA Annual Meeting showed that high adherence rates and favorable prostate-specific antigen (PSA) response were observed in men with nmCRPC who were treated with apalutamide.
Addition of Darolutamide to ADT Shows Comparable Safety Profile Among Patients With nmCRPC
September 16th 2021Patients with nonmetastatic castration-resistant prostate cancer often undergo prolonged treatment periods, making the safety profile of therapies like darolutamide an important factor in optimum treatment selection.
FDA OKs Adjuvant Nivolumab to Treat High-Risk Urothelial Carcinoma
August 20th 2021The Food and Drug Administration approved adjuvant nivolumab to treat urothelial carcinoma in patients who are at high risk of recurrence after undergoing radical resection, irrespective of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.